APO Research
Talk to an analyst

APO RESEARCH · REPORT

Pancreatic and Bile Duct Cancer Drug

Compare research editions
View pricing & licenses

Selected research

Industry Research

Pancreatic and Bile Duct Cancer Drug Industry Research Report 2026

22 December 2025144 pages

Choose your research edition.

Industry ResearchPancreatic and Bile Duct Cancer Drug Industry Research Report 2026144 pages · $2,950 USDIndustry Growth & TrendsGlobal Pancreatic and Bile Duct Cancer Drug Industry Growth and Trends Forecast to 2032120 pages · $3,450 USDMarket StructureGlobal Pancreatic and Bile Duct Cancer Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Pancreatic and Bile Duct Cancer Drug Market Outlook and Growth Opportunities 2026218 pages · $4,250 USDMarket Analysis & ForecastGlobal Pancreatic and Bile Duct Cancer Drug Market Analysis and Forecast 2026-2032212 pages · $4,950 USD

Market perspective

The global Pancreatic and Bile Duct Cancer Drug market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

North America: the Pancreatic and Bile Duct Cancer Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Pancreatic and Bile Duct Cancer Drug market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Pancreatic and Bile Duct Cancer Drug market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Pancreatic and Bile Duct Cancer Drug include Amgen Inc, ArQule Inc, ARMO Biosciences Inc, Aposense Ltd, Aphios Corp, Apexigen Inc, APEIRON Biologics AG, AntiCancer Inc and ANP Technologies Inc, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

Read the full market overview

This report quantifies the global Pancreatic and Bile Duct Cancer Drug market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Pancreatic and Bile Duct Cancer Drug.

Key Companies & Market Share Insights

This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Pancreatic and Bile Duct Cancer Drug Market by Company

Amgen Inc

ArQule Inc

ARMO Biosciences Inc

Aposense Ltd

Aphios Corp

Apexigen Inc

APEIRON Biologics AG

AntiCancer Inc

ANP Technologies Inc

Andarix Pharmaceuticals Inc

Anavex Life Sciences Corp

Amplia Therapeutics Pty Ltd

amcure GmbH

Altor BioScience Corp

Allinky Biopharma

Alligator Bioscience AB

Alissa Pharma

AIMM Therapeutics BV

AGV Discovery SAS

Advantagene Inc

Aduro BioTech Inc

Actuate Therapeutics Inc

Aclaris Therapeutics Inc

Ability Pharmaceuticals SL

AbGenomics International Inc

AbbVie Inc

AB Science SA

4SC AG

4P-Pharma SAS

3-V Biosciences Inc

Pancreatic and Bile Duct Cancer Drug Segment by Type

Vascular Endothelial Growth Factor Receptors

Signal Transducer Activator of Transcription 3

Programmed Cell Death Protein 1

Others

Pancreatic and Bile Duct Cancer Drug Segment by Application

Pancreatic Cancer

Cholangiocarcinoma

Pancreatic and Bile Duct Cancer Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Spain

Russia

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Saudi Arabia

Israel

United Arab Emirates

Turkey

Iran

Egypt

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Pancreatic and Bile Duct Cancer Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Pancreatic and Bile Duct Cancer Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Pancreatic and Bile Duct Cancer Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.

Chapter 6: Detailed analysis of Pancreatic and Bile Duct Cancer Drug companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 13: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Pancreatic and Bile Duct Cancer Drug Market Size by Type (2021-2026) & (US$ Million) Table 6. Global Pancreatic and Bile Duct Cancer Drug Revenue Market Share by Type (2021-2026) Table 7. Global Pancreatic and Bile Duct Cancer Drug Forecasted Market Size by Type (2027-2032) & (US$ Million) Table 8. Global Pancreatic and Bile Duct Cancer Drug Revenue Market Share by Type (2027-2032) Table 9. Global Pancreatic and Bile Duct Cancer Drug Market Size by Application (2021-2026) & (US$ Million) Table 10. Global Pancreatic and Bile Duct Cancer Drug Revenue Market Share by Application (2021-2026) Table 11. Global Pancreatic and Bile Duct Cancer Drug Forecasted Market Size by Application (2027-2032) & (US$ Million) Table 12. Global Pancreatic and Bile Duct Cancer Drug Revenue Market Share by Application (2027-2032) Table 13. Global Pancreatic and Bile Duct Cancer Drug Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 14. Global Pancreatic and Bile Duct Cancer Drug Market Size by Region (2021-2026) & (US$ Million) Table 15. Global Pancreatic and Bile Duct Cancer Drug Market Share by Region (2021-2026) Table 16. Global Pancreatic and Bile Duct Cancer Drug Forecasted Market Size by Region (2027-2032) & (US$ Million) Table 17. Global Pancreatic and Bile Duct Cancer Drug Market Share by Region (2027-2032) Table 18. Pancreatic and Bile Duct Cancer Drug Industry Trends Table 19. Pancreatic and Bile Duct Cancer Drug Industry Drivers Table 20. Pancreatic and Bile Duct Cancer Drug Industry Opportunities and Challenges Table 21. Pancreatic and Bile Duct Cancer Drug Market Restraints Table 22. Global Top Pancreatic and Bile Duct Cancer Drug Players by Revenue (US$ Million) & (2021-2026) Table 23. Global Pancreatic and Bile Duct Cancer Drug Revenue Market Share by Players (2021-2026) Table 24. Global Pancreatic and Bile Duct Cancer Drug Industry Players Ranking, 2024 VS 2025 VS 2026 Table 25. Global Key Players of Pancreatic and Bile Duct Cancer Drug, Headquarters and Area Served Table 26. Global Pancreatic and Bile Duct Cancer Drug Players, Product Type & Application Table 27. Global Players Market Concentration Ratio (CR5 and HHI) Table 28. Global Pancreatic and Bile Duct Cancer Drug by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 29. Players Mergers & Acquisitions, Expansion Plans Table 30. North America Pancreatic and Bile Duct Cancer Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 31. North America Pancreatic and Bile Duct Cancer Drug Market Size by Country (2021-2026) & (US$ Million) Table 32. North America Pancreatic and Bile Duct Cancer Drug Market Size by Country (2027-2032) & (US$ Million) Table 33. Europe Pancreatic and Bile Duct Cancer Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 34. Europe Pancreatic and Bile Duct Cancer Drug Market Size by Country (2021-2026) & (US$ Million) Table 35. Europe Pancreatic and Bile Duct Cancer Drug Market Size by Country (2027-2032) & (US$ Million) Table 36. Asia Pacific Pancreatic and Bile Duct Cancer Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 37. Asia Pacific Pancreatic and Bile Duct Cancer Drug Market Size by Region (2021-2026) & (US$ Million) Table 38. Asia Pacific Pancreatic and Bile Duct Cancer Drug Market Size by Country (2027-2032) & (US$ Million) Table 39. South America Pancreatic and Bile Duct Cancer Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 40. South America Pancreatic and Bile Duct Cancer Drug Market Size by Country (2021-2026) & (US$ Million) Table 41. South America Pancreatic and Bile Duct Cancer Drug Market Size by Country (2027-2032) & (US$ Million) Table 42. Middle East & Africa Pancreatic and Bile Duct Cancer Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 43. Middle East & Africa Pancreatic and Bile Duct Cancer Drug Market Size by Country (2021-2026) & (US$ Million) Table 44. Middle East & Africa Pancreatic and Bile Duct Cancer Drug Market Size by Country (2027-2032) & (US$ Million) Table 45. Amgen Inc Company Information Table 46. Amgen Inc Business Overview Table 47. Amgen Inc Revenue in Pancreatic and Bile Duct Cancer Drug Business (2021-2026) & (US$ Million) Table 48. Amgen Inc Pancreatic and Bile Duct Cancer Drug Product Portfolio Table 49. Amgen Inc Recent Developments Table 50. ArQule Inc Company Information Table 51. ArQule Inc Business Overview Table 52. ArQule Inc Revenue in Pancreatic and Bile Duct Cancer Drug Business (2021-2026) & (US$ Million) Table 53. ArQule Inc Pancreatic and Bile Duct Cancer Drug Product Portfolio Table 54. ArQule Inc Recent Developments Table 55. ARMO Biosciences Inc Company Information Table 56. ARMO Biosciences Inc Business Overview Table 57. ARMO Biosciences Inc Revenue in Pancreatic and Bile Duct Cancer Drug Business (2021-2026) & (US$ Million) Table 58. ARMO Biosciences Inc Pancreatic and Bile Duct Cancer Drug Product Portfolio Table 59. ARMO Biosciences Inc Recent Developments Table 60. Aposense Ltd Company Information Table 61. Aposense Ltd Business Overview Table 62. Aposense Ltd Revenue in Pancreatic and Bile Duct Cancer Drug Business (2021-2026) & (US$ Million) Table 63. Aposense Ltd Pancreatic and Bile Duct Cancer Drug Product Portfolio Table 64. Aposense Ltd Recent Developments Table 65. Aphios Corp Company Information Table 66. Aphios Corp Business Overview Table 67. Aphios Corp Revenue in Pancreatic and Bile Duct Cancer Drug Business (2021-2026) & (US$ Million) Table 68. Aphios Corp Pancreatic and Bile Duct Cancer Drug Product Portfolio Table 69. Aphios Corp Recent Developments Table 70. Apexigen Inc Company Information Table 71. Apexigen Inc Business Overview Table 72. Apexigen Inc Revenue in Pancreatic and Bile Duct Cancer Drug Business (2021-2026) & (US$ Million) Table 73. Apexigen Inc Pancreatic and Bile Duct Cancer Drug Product Portfolio Table 74. Apexigen Inc Recent Developments Table 75. APEIRON Biologics AG Company Information Table 76. APEIRON Biologics AG Business Overview Table 77. APEIRON Biologics AG Revenue in Pancreatic and Bile Duct Cancer Drug Business (2021-2026) & (US$ Million) Table 78. APEIRON Biologics AG Pancreatic and Bile Duct Cancer Drug Product Portfolio Table 79. APEIRON Biologics AG Recent Developments Table 80. AntiCancer Inc Company Information Table 81. AntiCancer Inc Business Overview Table 82. AntiCancer Inc Revenue in Pancreatic and Bile Duct Cancer Drug Business (2021-2026) & (US$ Million) Table 83. AntiCancer Inc Pancreatic and Bile Duct Cancer Drug Product Portfolio Table 84. AntiCancer Inc Recent Developments Table 85. ANP Technologies Inc Company Information Table 86. ANP Technologies Inc Business Overview Table 87. ANP Technologies Inc Revenue in Pancreatic and Bile Duct Cancer Drug Business (2021-2026) & (US$ Million) Table 88. ANP Technologies Inc Pancreatic and Bile Duct Cancer Drug Product Portfolio Table 89. ANP Technologies Inc Recent Developments Table 90. Andarix Pharmaceuticals Inc Company Information Table 91. Andarix Pharmaceuticals Inc Business Overview Table 92. Andarix Pharmaceuticals Inc Revenue in Pancreatic and Bile Duct Cancer Drug Business (2021-2026) & (US$ Million) Table 93. Andarix Pharmaceuticals Inc Pancreatic and Bile Duct Cancer Drug Product Portfolio Table 94. Andarix Pharmaceuticals Inc Recent Developments Table 95. Anavex Life Sciences Corp Company Information Table 96. Anavex Life Sciences Corp Business Overview Table 97. Anavex Life Sciences Corp Revenue in Pancreatic and Bile Duct Cancer Drug Business (2021-2026) & (US$ Million) Table 98. Anavex Life Sciences Corp Pancreatic and Bile Duct Cancer Drug Product Portfolio Table 99. Anavex Life Sciences Corp Recent Developments Table 100. Amplia Therapeutics Pty Ltd Company Information Table 101. Amplia Therapeutics Pty Ltd Business Overview Table 102. Amplia Therapeutics Pty Ltd Revenue in Pancreatic and Bile Duct Cancer Drug Business (2021-2026) & (US$ Million) Table 103. Amplia Therapeutics Pty Ltd Pancreatic and Bile Duct Cancer Drug Product Portfolio Table 104. Amplia Therapeutics Pty Ltd Recent Developments Table 105. amcure GmbH Company Information Table 106. amcure GmbH Business Overview Table 107. amcure GmbH Revenue in Pancreatic and Bile Duct Cancer Drug Business (2021-2026) & (US$ Million) Table 108. amcure GmbH Pancreatic and Bile Duct Cancer Drug Product Portfolio Table 109. amcure GmbH Recent Developments Table 110. Altor BioScience Corp Company Information Table 111. Altor BioScience Corp Business Overview Table 112. Altor BioScience Corp Revenue in Pancreatic and Bile Duct Cancer Drug Business (2021-2026) & (US$ Million) Table 113. Altor BioScience Corp Pancreatic and Bile Duct Cancer Drug Product Portfolio Table 114. Altor BioScience Corp Recent Developments Table 115. Allinky Biopharma Company Information Table 116. Allinky Biopharma Business Overview Table 117. Allinky Biopharma Revenue in Pancreatic and Bile Duct Cancer Drug Business (2021-2026) & (US$ Million) Table 118. Allinky Biopharma Pancreatic and Bile Duct Cancer Drug Product Portfolio Table 119. Allinky Biopharma Recent Developments Table 120. Alligator Bioscience AB Company Information Table 121. Alligator Bioscience AB Business Overview Table 122. Alligator Bioscience AB Revenue in Pancreatic and Bile Duct Cancer Drug Business (2021-2026) & (US$ Million) Table 123. Alligator Bioscience AB Pancreatic and Bile Duct Cancer Drug Product Portfolio Table 124. Alligator Bioscience AB Recent Developments Table 125. Alissa Pharma Company Information Table 126. Alissa Pharma Business Overview Table 127. Alissa Pharma Revenue in Pancreatic and Bile Duct Cancer Drug Business (2021-2026) & (US$ Million) Table 128. Alissa Pharma Pancreatic and Bile Duct Cancer Drug Product Portfolio Table 129. Alissa Pharma Recent Developments Table 130. AIMM Therapeutics BV Company Information Table 131. AIMM Therapeutics BV Business Overview Table 132. AIMM Therapeutics BV Revenue in Pancreatic and Bile Duct Cancer Drug Business (2021-2026) & (US$ Million) Table 133. AIMM Therapeutics BV Pancreatic and Bile Duct Cancer Drug Product Portfolio Table 134. AIMM Therapeutics BV Recent Developments Table 135. AGV Discovery SAS Company Information Table 136. AGV Discovery SAS Business Overview Table 137. AGV Discovery SAS Revenue in Pancreatic and Bile Duct Cancer Drug Business (2021-2026) & (US$ Million) Table 138. AGV Discovery SAS Pancreatic and Bile Duct Cancer Drug Product Portfolio Table 139. AGV Discovery SAS Recent Developments Table 140. Advantagene Inc Company Information Table 141. Advantagene Inc Business Overview Table 142. Advantagene Inc Revenue in Pancreatic and Bile Duct Cancer Drug Business (2021-2026) & (US$ Million) Table 143. Advantagene Inc Pancreatic and Bile Duct Cancer Drug Product Portfolio Table 144. Advantagene Inc Recent Developments Table 145. Aduro BioTech Inc Company Information Table 146. Aduro BioTech Inc Business Overview Table 147. Aduro BioTech Inc Revenue in Pancreatic and Bile Duct Cancer Drug Business (2021-2026) & (US$ Million) Table 148. Aduro BioTech Inc Pancreatic and Bile Duct Cancer Drug Product Portfolio Table 149. Aduro BioTech Inc Recent Developments Table 150. Actuate Therapeutics Inc Company Information Table 151. Actuate Therapeutics Inc Business Overview Table 152. Actuate Therapeutics Inc Revenue in Pancreatic and Bile Duct Cancer Drug Business (2021-2026) & (US$ Million) Table 153. Actuate Therapeutics Inc Pancreatic and Bile Duct Cancer Drug Product Portfolio Table 154. Actuate Therapeutics Inc Recent Developments Table 155. Aclaris Therapeutics Inc Company Information Table 156. Aclaris Therapeutics Inc Business Overview Table 157. Aclaris Therapeutics Inc Revenue in Pancreatic and Bile Duct Cancer Drug Business (2021-2026) & (US$ Million) Table 158. Aclaris Therapeutics Inc Pancreatic and Bile Duct Cancer Drug Product Portfolio Table 159. Aclaris Therapeutics Inc Recent Developments Table 160. Ability Pharmaceuticals SL Company Information Table 161. Ability Pharmaceuticals SL Business Overview Table 162. Ability Pharmaceuticals SL Revenue in Pancreatic and Bile Duct Cancer Drug Business (2021-2026) & (US$ Million) Table 163. Ability Pharmaceuticals SL Pancreatic and Bile Duct Cancer Drug Product Portfolio Table 164. Ability Pharmaceuticals SL Recent Developments Table 165. AbGenomics International Inc Company Information Table 166. AbGenomics International Inc Business Overview Table 167. AbGenomics International Inc Revenue in Pancreatic and Bile Duct Cancer Drug Business (2021-2026) & (US$ Million) Table 168. AbGenomics International Inc Pancreatic and Bile Duct Cancer Drug Product Portfolio Table 169. AbGenomics International Inc Recent Developments Table 170. AbbVie Inc Company Information Table 171. AbbVie Inc Business Overview Table 172. AbbVie Inc Revenue in Pancreatic and Bile Duct Cancer Drug Business (2021-2026) & (US$ Million) Table 173. AbbVie Inc Pancreatic and Bile Duct Cancer Drug Product Portfolio Table 174. AbbVie Inc Recent Developments Table 175. AB Science SA Company Information Table 176. AB Science SA Business Overview Table 177. AB Science SA Revenue in Pancreatic and Bile Duct Cancer Drug Business (2021-2026) & (US$ Million) Table 178. AB Science SA Pancreatic and Bile Duct Cancer Drug Product Portfolio Table 179. AB Science SA Recent Developments Table 180. 4SC AG Company Information Table 181. 4SC AG Business Overview Table 182. 4SC AG Revenue in Pancreatic and Bile Duct Cancer Drug Business (2021-2026) & (US$ Million) Table 183. 4SC AG Pancreatic and Bile Duct Cancer Drug Product Portfolio Table 184. 4SC AG Recent Developments Table 185. 4P-Pharma SAS Company Information Table 186. 4P-Pharma SAS Business Overview Table 187. 4P-Pharma SAS Revenue in Pancreatic and Bile Duct Cancer Drug Business (2021-2026) & (US$ Million) Table 188. 4P-Pharma SAS Pancreatic and Bile Duct Cancer Drug Product Portfolio Table 189. 4P-Pharma SAS Recent Developments Table 190. 3-V Biosciences Inc Company Information Table 191. 3-V Biosciences Inc Business Overview Table 192. 3-V Biosciences Inc Revenue in Pancreatic and Bile Duct Cancer Drug Business (2021-2026) & (US$ Million) Table 193. 3-V Biosciences Inc Pancreatic and Bile Duct Cancer Drug Product Portfolio Table 194. 3-V Biosciences Inc Recent Developments Table 195. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Pancreatic and Bile Duct Cancer Drug Product Image Figure 5. Global Pancreatic and Bile Duct Cancer Drug Market Size Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 6. Global Pancreatic and Bile Duct Cancer Drug Market Share by Type: 2025 VS 2032 Figure 7. Vascular Endothelial Growth Factor Receptors Product Figure 8. Signal Transducer Activator of Transcription 3 Product Figure 9. Programmed Cell Death Protein 1 Product Figure 10. Others Product Figure 11. Global Pancreatic and Bile Duct Cancer Drug Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 12. Global Pancreatic and Bile Duct Cancer Drug Market Share by Application: 2025 VS 2032 Figure 13. Pancreatic Cancer Product Figure 14. Cholangiocarcinoma Product Figure 15. Global Pancreatic and Bile Duct Cancer Drug Market Size (US$ Million), Year-over-Year: 2021-2032 Figure 16. Global Pancreatic and Bile Duct Cancer Drug Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 17. Global Pancreatic and Bile Duct Cancer Drug Market Share by Region: 2025 VS 2032 Figure 18. Global Pancreatic and Bile Duct Cancer Drug Market Share by Players in 2025 Figure 19. Global Pancreatic and Bile Duct Cancer Drug Manufacturers Established Date Figure 20. Global Top 5 and 10 Pancreatic and Bile Duct Cancer Drug Players Market Share by Revenue in 2025 Figure 21. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 22. North America Pancreatic and Bile Duct Cancer Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 23. North America Pancreatic and Bile Duct Cancer Drug Market Share by Country (2021-2032) Figure 24. United States Pancreatic and Bile Duct Cancer Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 25. Canada Pancreatic and Bile Duct Cancer Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 26. Mexico Pancreatic and Bile Duct Cancer Drug Market Share by Country (2021-2032) Figure 27. Europe Pancreatic and Bile Duct Cancer Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 28. Europe Pancreatic and Bile Duct Cancer Drug Market Share by Country (2021-2032) Figure 29. Germany Pancreatic and Bile Duct Cancer Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 30. France Pancreatic and Bile Duct Cancer Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 31. U.K. Pancreatic and Bile Duct Cancer Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 32. Italy Pancreatic and Bile Duct Cancer Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 33. Spain Pancreatic and Bile Duct Cancer Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 34. Russia Pancreatic and Bile Duct Cancer Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 35. Netherlands Pancreatic and Bile Duct Cancer Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 36. Nordic Countries Pancreatic and Bile Duct Cancer Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 37. Asia-Pacific Pancreatic and Bile Duct Cancer Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 38. Asia-Pacific Pancreatic and Bile Duct Cancer Drug Market Share by Country (2021-2032) Figure 39. China Pancreatic and Bile Duct Cancer Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 40. Japan Pancreatic and Bile Duct Cancer Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 41. South Korea Pancreatic and Bile Duct Cancer Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 42. India Pancreatic and Bile Duct Cancer Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 43. India Pancreatic and Bile Duct Cancer Drug Market Share by Country (2021-2032) Figure 44. Australia Pancreatic and Bile Duct Cancer Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 45. China Taiwan Pancreatic and Bile Duct Cancer Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 46. Southeast Asia Pancreatic and Bile Duct Cancer Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 47. South America Pancreatic and Bile Duct Cancer Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 48. South America Pancreatic and Bile Duct Cancer Drug Market Share by Country (2021-2032) Figure 49. Brazil Pancreatic and Bile Duct Cancer Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 50. Argentina Pancreatic and Bile Duct Cancer Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 51. Chile Pancreatic and Bile Duct Cancer Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 52. Colombia Pancreatic and Bile Duct Cancer Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 53. Peru Pancreatic and Bile Duct Cancer Drug Market Size YoY Growth (2021-2032) & (US$ Million) Figure 54. Amgen Inc Revenue Growth Rate in Pancreatic and Bile Duct Cancer Drug Business (2021-2026) Figure 55. ArQule Inc Revenue Growth Rate in Pancreatic and Bile Duct Cancer Drug Business (2021-2026) Figure 56. ARMO Biosciences Inc Revenue Growth Rate in Pancreatic and Bile Duct Cancer Drug Business (2021-2026) Figure 57. Aposense Ltd Revenue Growth Rate in Pancreatic and Bile Duct Cancer Drug Business (2021-2026) Figure 58. Aphios Corp Revenue Growth Rate in Pancreatic and Bile Duct Cancer Drug Business (2021-2026) Figure 59. Apexigen Inc Revenue Growth Rate in Pancreatic and Bile Duct Cancer Drug Business (2021-2026) Figure 60. APEIRON Biologics AG Revenue Growth Rate in Pancreatic and Bile Duct Cancer Drug Business (2021-2026) Figure 61. AntiCancer Inc Revenue Growth Rate in Pancreatic and Bile Duct Cancer Drug Business (2021-2026) Figure 62. ANP Technologies Inc Revenue Growth Rate in Pancreatic and Bile Duct Cancer Drug Business (2021-2026) Figure 63. Andarix Pharmaceuticals Inc Revenue Growth Rate in Pancreatic and Bile Duct Cancer Drug Business (2021-2026) Figure 64. Anavex Life Sciences Corp Revenue Growth Rate in Pancreatic and Bile Duct Cancer Drug Business (2021-2026) Figure 65. Amplia Therapeutics Pty Ltd Revenue Growth Rate in Pancreatic and Bile Duct Cancer Drug Business (2021-2026) Figure 66. amcure GmbH Revenue Growth Rate in Pancreatic and Bile Duct Cancer Drug Business (2021-2026) Figure 67. Altor BioScience Corp Revenue Growth Rate in Pancreatic and Bile Duct Cancer Drug Business (2021-2026) Figure 68. Allinky Biopharma Revenue Growth Rate in Pancreatic and Bile Duct Cancer Drug Business (2021-2026) Figure 69. Alligator Bioscience AB Revenue Growth Rate in Pancreatic and Bile Duct Cancer Drug Business (2021-2026) Figure 70. Alissa Pharma Revenue Growth Rate in Pancreatic and Bile Duct Cancer Drug Business (2021-2026) Figure 71. AIMM Therapeutics BV Revenue Growth Rate in Pancreatic and Bile Duct Cancer Drug Business (2021-2026) Figure 72. AGV Discovery SAS Revenue Growth Rate in Pancreatic and Bile Duct Cancer Drug Business (2021-2026) Figure 73. Advantagene Inc Revenue Growth Rate in Pancreatic and Bile Duct Cancer Drug Business (2021-2026) Figure 74. Aduro BioTech Inc Revenue Growth Rate in Pancreatic and Bile Duct Cancer Drug Business (2021-2026) Figure 75. Actuate Therapeutics Inc Revenue Growth Rate in Pancreatic and Bile Duct Cancer Drug Business (2021-2026) Figure 76. Aclaris Therapeutics Inc Revenue Growth Rate in Pancreatic and Bile Duct Cancer Drug Business (2021-2026) Figure 77. Ability Pharmaceuticals SL Revenue Growth Rate in Pancreatic and Bile Duct Cancer Drug Business (2021-2026) Figure 78. AbGenomics International Inc Revenue Growth Rate in Pancreatic and Bile Duct Cancer Drug Business (2021-2026) Figure 79. AbbVie Inc Revenue Growth Rate in Pancreatic and Bile Duct Cancer Drug Business (2021-2026) Figure 80. AB Science SA Revenue Growth Rate in Pancreatic and Bile Duct Cancer Drug Business (2021-2026) Figure 81. 4SC AG Revenue Growth Rate in Pancreatic and Bile Duct Cancer Drug Business (2021-2026) Figure 82. 4P-Pharma SAS Revenue Growth Rate in Pancreatic and Bile Duct Cancer Drug Business (2021-2026) Figure 83. 3-V Biosciences Inc Revenue Growth Rate in Pancreatic and Bile Duct Cancer Drug Business (2021-2026)

Scope & coverage.

Types
  • Vascular Endothelial Growth Factor Receptors
  • Signal Transducer Activator of Transcription 3
  • Programmed Cell Death Protein 1
  • Others
Applications
  • Pancreatic Cancer
  • Cholangiocarcinoma
Companies covered
  • Amgen Inc
  • ArQule Inc
  • ARMO Biosciences Inc
  • Aposense Ltd
  • Aphios Corp
  • Apexigen Inc
  • APEIRON Biologics AG
  • AntiCancer Inc
  • ANP Technologies Inc
  • Andarix Pharmaceuticals Inc
  • Anavex Life Sciences Corp
  • Amplia Therapeutics Pty Ltd
  • amcure GmbH
  • Altor BioScience Corp
  • Allinky Biopharma
  • Alligator Bioscience AB
  • Alissa Pharma
  • AIMM Therapeutics BV
  • AGV Discovery SAS
  • Advantagene Inc
  • Aduro BioTech Inc
  • Actuate Therapeutics Inc
  • Aclaris Therapeutics Inc
  • Ability Pharmaceuticals SL
  • AbGenomics International Inc
  • AbbVie Inc
  • AB Science SA
  • 4SC AG
  • 4P-Pharma SAS
  • 3-V Biosciences Inc

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Pancreatic and Bile Duct Cancer Drug by Type
  3. 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
  4. 2.2.2 Vascular Endothelial Growth Factor Receptors
  5. 2.2.3 Signal Transducer Activator of Transcription 3
  6. 2.2.4 Programmed Cell Death Protein 1
  7. 2.2.5 Others
  8. 2.3 Pancreatic and Bile Duct Cancer Drug by Application
  9. 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  10. 2.3.2 Pancreatic Cancer
  11. 2.3.3 Cholangiocarcinoma
  12. 2.4 Assumptions and Limitations
3 Pancreatic and Bile Duct Cancer Drug Breakdown Data by Type
  1. 3.1 Global Pancreatic and Bile Duct Cancer Drug Historic Market Size by Type (2021-2026)
  2. 3.2 Global Pancreatic and Bile Duct Cancer Drug Forecasted Market Size by Type (2027-2032)
4 Pancreatic and Bile Duct Cancer Drug Breakdown Data by Application
  1. 4.1 Global Pancreatic and Bile Duct Cancer Drug Historic Market Size by Application (2021-2026)
  2. 4.2 Global Pancreatic and Bile Duct Cancer Drug Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
  1. 5.1 Global Pancreatic and Bile Duct Cancer Drug Market Perspective (2021-2032)
  2. 5.2 Global Pancreatic and Bile Duct Cancer Drug Growth Trends by Region
  3. 5.2.1 Global Pancreatic and Bile Duct Cancer Drug Market Size by Region: 2021 VS 2025 VS 2032
  4. 5.2.2 Pancreatic and Bile Duct Cancer Drug Historic Market Size by Region (2021-2026)
  5. 5.2.3 Pancreatic and Bile Duct Cancer Drug Forecasted Market Size by Region (2027-2032)
  6. 5.3 Pancreatic and Bile Duct Cancer Drug Market Dynamics
  7. 5.3.1 Pancreatic and Bile Duct Cancer Drug Industry Trends
  8. 5.3.2 Pancreatic and Bile Duct Cancer Drug Market Drivers
  9. 5.3.3 Pancreatic and Bile Duct Cancer Drug Market Challenges
  10. 5.3.4 Pancreatic and Bile Duct Cancer Drug Market Restraints
6 Market Competitive Landscape by Players
  1. 6.1 Global Top Pancreatic and Bile Duct Cancer Drug Players by Revenue
  2. 6.1.1 Global Top Pancreatic and Bile Duct Cancer Drug Players by Revenue (2021-2026)
  3. 6.1.2 Global Pancreatic and Bile Duct Cancer Drug Revenue Market Share by Players (2021-2026)
  4. 6.2 Global Pancreatic and Bile Duct Cancer Drug Industry Players Ranking, 2023 VS 2024 VS 2025
  5. 6.3 Global Key Players of Pancreatic and Bile Duct Cancer Drug Head Office and Area Served
  6. 6.4 Global Pancreatic and Bile Duct Cancer Drug Players, Product Type & Application
  7. 6.5 Global Pancreatic and Bile Duct Cancer Drug Manufacturers Established Date
  8. 6.6 Global Pancreatic and Bile Duct Cancer Drug Market CR5 and HHI
  9. 6.7 Global Players Mergers & Acquisition
7 North America
  1. 7.1 North America Pancreatic and Bile Duct Cancer Drug Market Size (2021-2032)
  2. 7.2 North America Pancreatic and Bile Duct Cancer Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
  3. 7.3 North America Pancreatic and Bile Duct Cancer Drug Market Size by Country (2021-2026)
  4. 7.4 North America Pancreatic and Bile Duct Cancer Drug Market Size by Country (2027-2032)
  5. 7.5 United States
  6. 7.5 United States
  7. 7.6 Canada
  8. 7.7 Mexico
8 Europe
  1. 8.1 Europe Pancreatic and Bile Duct Cancer Drug Market Size (2021-2032)
  2. 8.2 Europe Pancreatic and Bile Duct Cancer Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
  3. 8.3 Europe Pancreatic and Bile Duct Cancer Drug Market Size by Country (2021-2026)
  4. 8.4 Europe Pancreatic and Bile Duct Cancer Drug Market Size by Country (2027-2032)
  5. 8.5 Germany
  6. 8.6 France
  7. 8.7 U.K.
  8. 8.8 Italy
  9. 8.9 Spain
  10. 8.10 Russia
  11. 8.11 Netherlands
  12. 8.12 Nordic Countries
9 Asia-Pacific
  1. 9.1 Asia-Pacific Pancreatic and Bile Duct Cancer Drug Market Size (2021-2032)
  2. 9.2 Asia-Pacific Pancreatic and Bile Duct Cancer Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
  3. 9.3 Asia-Pacific Pancreatic and Bile Duct Cancer Drug Market Size by Country (2021-2026)
  4. 9.4 Asia-Pacific Pancreatic and Bile Duct Cancer Drug Market Size by Country (2027-2032)
  5. 9.5 China
  6. 9.6 Japan
  7. 9.7 South Korea
  8. 9.8 India
  9. 9.9 Australia
  10. 9.10 China Taiwan
  11. 9.11 Southeast Asia
10 South America
  1. 10.1 South America Pancreatic and Bile Duct Cancer Drug Market Size (2021-2032)
  2. 10.2 South America Pancreatic and Bile Duct Cancer Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
  3. 10.3 South America Pancreatic and Bile Duct Cancer Drug Market Size by Country (2021-2026)
  4. 10.4 South America Pancreatic and Bile Duct Cancer Drug Market Size by Country (2027-2032)
  5. 10.5 Brazil
  6. 10.6 Argentina
  7. 10.7 Chile
  8. 10.8 Colombia
  9. 10.9 Peru
11 Middle East & Africa
  1. 11.1 Middle East & Africa Pancreatic and Bile Duct Cancer Drug Market Size (2021-2032)
  2. 11.2 Middle East & Africa Pancreatic and Bile Duct Cancer Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
  3. 11.3 Middle East & Africa Pancreatic and Bile Duct Cancer Drug Market Size by Country (2021-2026)
  4. 11.4 Middle East & Africa Pancreatic and Bile Duct Cancer Drug Market Size by Country (2027-2032)
  5. 11.5 Saudi Arabia
  6. 11.6 Israel
  7. 11.7 United Arab Emirates
  8. 11.8 Turkey
  9. 11.9 Iran
  10. 11.10 Egypt
12 Players Profiled
  1. 12.1 Amgen Inc
  2. 12.1.1 Amgen Inc Company Information
  3. 12.1.2 Amgen Inc Business Overview
  4. 12.1.3 Amgen Inc Revenue in Pancreatic and Bile Duct Cancer Drug Business (2021-2026)
  5. 12.1.4 Amgen Inc Pancreatic and Bile Duct Cancer Drug Product Portfolio
  6. 12.1.5 Amgen Inc Recent Developments
  7. 12.2 ArQule Inc
  8. 12.2.1 ArQule Inc Company Information
  9. 12.2.2 ArQule Inc Business Overview
  10. 12.2.3 ArQule Inc Revenue in Pancreatic and Bile Duct Cancer Drug Business (2021-2026)
  11. 12.2.4 ArQule Inc Pancreatic and Bile Duct Cancer Drug Product Portfolio
  12. 12.2.5 ArQule Inc Recent Developments
  13. 12.3 ARMO Biosciences Inc
  14. 12.3.1 ARMO Biosciences Inc Company Information
  15. 12.3.2 ARMO Biosciences Inc Business Overview
  16. 12.3.3 ARMO Biosciences Inc Revenue in Pancreatic and Bile Duct Cancer Drug Business (2021-2026)
  17. 12.3.4 ARMO Biosciences Inc Pancreatic and Bile Duct Cancer Drug Product Portfolio
  18. 12.3.5 ARMO Biosciences Inc Recent Developments
  19. 12.4 Aposense Ltd
  20. 12.4.1 Aposense Ltd Company Information
  21. 12.4.2 Aposense Ltd Business Overview
  22. 12.4.3 Aposense Ltd Revenue in Pancreatic and Bile Duct Cancer Drug Business (2021-2026)
  23. 12.4.4 Aposense Ltd Pancreatic and Bile Duct Cancer Drug Product Portfolio
  24. 12.4.5 Aposense Ltd Recent Developments
  25. 12.5 Aphios Corp
  26. 12.5.1 Aphios Corp Company Information
  27. 12.5.2 Aphios Corp Business Overview
  28. 12.5.3 Aphios Corp Revenue in Pancreatic and Bile Duct Cancer Drug Business (2021-2026)
  29. 12.5.4 Aphios Corp Pancreatic and Bile Duct Cancer Drug Product Portfolio
  30. 12.5.5 Aphios Corp Recent Developments
  31. 12.6 Apexigen Inc
  32. 12.6.1 Apexigen Inc Company Information
  33. 12.6.2 Apexigen Inc Business Overview
  34. 12.6.3 Apexigen Inc Revenue in Pancreatic and Bile Duct Cancer Drug Business (2021-2026)
  35. 12.6.4 Apexigen Inc Pancreatic and Bile Duct Cancer Drug Product Portfolio
  36. 12.6.5 Apexigen Inc Recent Developments
  37. 12.7 APEIRON Biologics AG
  38. 12.7.1 APEIRON Biologics AG Company Information
  39. 12.7.2 APEIRON Biologics AG Business Overview
  40. 12.7.3 APEIRON Biologics AG Revenue in Pancreatic and Bile Duct Cancer Drug Business (2021-2026)
  41. 12.7.4 APEIRON Biologics AG Pancreatic and Bile Duct Cancer Drug Product Portfolio
  42. 12.7.5 APEIRON Biologics AG Recent Developments
  43. 12.8 AntiCancer Inc
  44. 12.8.1 AntiCancer Inc Company Information
  45. 12.8.2 AntiCancer Inc Business Overview
  46. 12.8.3 AntiCancer Inc Revenue in Pancreatic and Bile Duct Cancer Drug Business (2021-2026)
  47. 12.8.4 AntiCancer Inc Pancreatic and Bile Duct Cancer Drug Product Portfolio
  48. 12.8.5 AntiCancer Inc Recent Developments
  49. 12.9 ANP Technologies Inc
  50. 12.9.1 ANP Technologies Inc Company Information
  51. 12.9.2 ANP Technologies Inc Business Overview
  52. 12.9.3 ANP Technologies Inc Revenue in Pancreatic and Bile Duct Cancer Drug Business (2021-2026)
  53. 12.9.4 ANP Technologies Inc Pancreatic and Bile Duct Cancer Drug Product Portfolio
  54. 12.9.5 ANP Technologies Inc Recent Developments
  55. 12.10 Andarix Pharmaceuticals Inc
  56. 12.10.1 Andarix Pharmaceuticals Inc Company Information
  57. 12.10.2 Andarix Pharmaceuticals Inc Business Overview
  58. 12.10.3 Andarix Pharmaceuticals Inc Revenue in Pancreatic and Bile Duct Cancer Drug Business (2021-2026)
  59. 12.10.4 Andarix Pharmaceuticals Inc Pancreatic and Bile Duct Cancer Drug Product Portfolio
  60. 12.10.5 Andarix Pharmaceuticals Inc Recent Developments
  61. 12.11 Anavex Life Sciences Corp
  62. 12.11.1 Anavex Life Sciences Corp Company Information
  63. 12.11.2 Anavex Life Sciences Corp Business Overview
  64. 12.11.3 Anavex Life Sciences Corp Revenue in Pancreatic and Bile Duct Cancer Drug Business (2021-2026)
  65. 12.11.4 Anavex Life Sciences Corp Pancreatic and Bile Duct Cancer Drug Product Portfolio
  66. 12.11.5 Anavex Life Sciences Corp Recent Developments
  67. 12.12 Amplia Therapeutics Pty Ltd
  68. 12.12.1 Amplia Therapeutics Pty Ltd Company Information
  69. 12.12.2 Amplia Therapeutics Pty Ltd Business Overview
  70. 12.12.3 Amplia Therapeutics Pty Ltd Revenue in Pancreatic and Bile Duct Cancer Drug Business (2021-2026)
  71. 12.12.4 Amplia Therapeutics Pty Ltd Pancreatic and Bile Duct Cancer Drug Product Portfolio
  72. 12.12.5 Amplia Therapeutics Pty Ltd Recent Developments
  73. 12.13 amcure GmbH
  74. 12.13.1 amcure GmbH Company Information
  75. 12.13.2 amcure GmbH Business Overview
  76. 12.13.3 amcure GmbH Revenue in Pancreatic and Bile Duct Cancer Drug Business (2021-2026)
  77. 12.13.4 amcure GmbH Pancreatic and Bile Duct Cancer Drug Product Portfolio
  78. 12.13.5 amcure GmbH Recent Developments
  79. 12.14 Altor BioScience Corp
  80. 12.14.1 Altor BioScience Corp Company Information
  81. 12.14.2 Altor BioScience Corp Business Overview
  82. 12.14.3 Altor BioScience Corp Revenue in Pancreatic and Bile Duct Cancer Drug Business (2021-2026)
  83. 12.14.4 Altor BioScience Corp Pancreatic and Bile Duct Cancer Drug Product Portfolio
  84. 12.14.5 Altor BioScience Corp Recent Developments
  85. 12.15 Allinky Biopharma
  86. 12.15.1 Allinky Biopharma Company Information
  87. 12.15.2 Allinky Biopharma Business Overview
  88. 12.15.3 Allinky Biopharma Revenue in Pancreatic and Bile Duct Cancer Drug Business (2021-2026)
  89. 12.15.4 Allinky Biopharma Pancreatic and Bile Duct Cancer Drug Product Portfolio
  90. 12.15.5 Allinky Biopharma Recent Developments
  91. 12.16 Alligator Bioscience AB
  92. 12.16.1 Alligator Bioscience AB Company Information
  93. 12.16.2 Alligator Bioscience AB Business Overview
  94. 12.16.3 Alligator Bioscience AB Revenue in Pancreatic and Bile Duct Cancer Drug Business (2021-2026)
  95. 12.16.4 Alligator Bioscience AB Pancreatic and Bile Duct Cancer Drug Product Portfolio
  96. 12.16.5 Alligator Bioscience AB Recent Developments
  97. 12.17 Alissa Pharma
  98. 12.17.1 Alissa Pharma Company Information
  99. 12.17.2 Alissa Pharma Business Overview
  100. 12.17.3 Alissa Pharma Revenue in Pancreatic and Bile Duct Cancer Drug Business (2021-2026)
  101. 12.17.4 Alissa Pharma Pancreatic and Bile Duct Cancer Drug Product Portfolio
  102. 12.17.5 Alissa Pharma Recent Developments
  103. 12.18 AIMM Therapeutics BV
  104. 12.18.1 AIMM Therapeutics BV Company Information
  105. 12.18.2 AIMM Therapeutics BV Business Overview
  106. 12.18.3 AIMM Therapeutics BV Revenue in Pancreatic and Bile Duct Cancer Drug Business (2021-2026)
  107. 12.18.4 AIMM Therapeutics BV Pancreatic and Bile Duct Cancer Drug Product Portfolio
  108. 12.18.5 AIMM Therapeutics BV Recent Developments
  109. 12.19 AGV Discovery SAS
  110. 12.19.1 AGV Discovery SAS Company Information
  111. 12.19.2 AGV Discovery SAS Business Overview
  112. 12.19.3 AGV Discovery SAS Revenue in Pancreatic and Bile Duct Cancer Drug Business (2021-2026)
  113. 12.19.4 AGV Discovery SAS Pancreatic and Bile Duct Cancer Drug Product Portfolio
  114. 12.19.5 AGV Discovery SAS Recent Developments
  115. 12.20 Advantagene Inc
  116. 12.20.1 Advantagene Inc Company Information
  117. 12.20.2 Advantagene Inc Business Overview
  118. 12.20.3 Advantagene Inc Revenue in Pancreatic and Bile Duct Cancer Drug Business (2021-2026)
  119. 12.20.4 Advantagene Inc Pancreatic and Bile Duct Cancer Drug Product Portfolio
  120. 12.20.5 Advantagene Inc Recent Developments
  121. 12.21 Aduro BioTech Inc
  122. 12.21.1 Aduro BioTech Inc Company Information
  123. 12.21.2 Aduro BioTech Inc Business Overview
  124. 12.21.3 Aduro BioTech Inc Revenue in Pancreatic and Bile Duct Cancer Drug Business (2021-2026)
  125. 12.21.4 Aduro BioTech Inc Pancreatic and Bile Duct Cancer Drug Product Portfolio
  126. 12.21.5 Aduro BioTech Inc Recent Developments
  127. 12.22 Actuate Therapeutics Inc
  128. 12.22.1 Actuate Therapeutics Inc Company Information
  129. 12.22.2 Actuate Therapeutics Inc Business Overview
  130. 12.22.3 Actuate Therapeutics Inc Revenue in Pancreatic and Bile Duct Cancer Drug Business (2021-2026)
  131. 12.22.4 Actuate Therapeutics Inc Pancreatic and Bile Duct Cancer Drug Product Portfolio
  132. 12.22.5 Actuate Therapeutics Inc Recent Developments
  133. 12.23 Aclaris Therapeutics Inc
  134. 12.23.1 Aclaris Therapeutics Inc Company Information
  135. 12.23.2 Aclaris Therapeutics Inc Business Overview
  136. 12.23.3 Aclaris Therapeutics Inc Revenue in Pancreatic and Bile Duct Cancer Drug Business (2021-2026)
  137. 12.23.4 Aclaris Therapeutics Inc Pancreatic and Bile Duct Cancer Drug Product Portfolio
  138. 12.23.5 Aclaris Therapeutics Inc Recent Developments
  139. 12.24 Ability Pharmaceuticals SL
  140. 12.24.1 Ability Pharmaceuticals SL Company Information
  141. 12.24.2 Ability Pharmaceuticals SL Business Overview
  142. 12.24.3 Ability Pharmaceuticals SL Revenue in Pancreatic and Bile Duct Cancer Drug Business (2021-2026)
  143. 12.24.4 Ability Pharmaceuticals SL Pancreatic and Bile Duct Cancer Drug Product Portfolio
  144. 12.24.5 Ability Pharmaceuticals SL Recent Developments
  145. 12.25 AbGenomics International Inc
  146. 12.25.1 AbGenomics International Inc Company Information
  147. 12.25.2 AbGenomics International Inc Business Overview
  148. 12.25.3 AbGenomics International Inc Revenue in Pancreatic and Bile Duct Cancer Drug Business (2021-2026)
  149. 12.25.4 AbGenomics International Inc Pancreatic and Bile Duct Cancer Drug Product Portfolio
  150. 12.25.5 AbGenomics International Inc Recent Developments
  151. 12.26 AbbVie Inc
  152. 12.26.1 AbbVie Inc Company Information
  153. 12.26.2 AbbVie Inc Business Overview
  154. 12.26.3 AbbVie Inc Revenue in Pancreatic and Bile Duct Cancer Drug Business (2021-2026)
  155. 12.26.4 AbbVie Inc Pancreatic and Bile Duct Cancer Drug Product Portfolio
  156. 12.26.5 AbbVie Inc Recent Developments
  157. 12.27 AB Science SA
  158. 12.27.1 AB Science SA Company Information
  159. 12.27.2 AB Science SA Business Overview
  160. 12.27.3 AB Science SA Revenue in Pancreatic and Bile Duct Cancer Drug Business (2021-2026)
  161. 12.27.4 AB Science SA Pancreatic and Bile Duct Cancer Drug Product Portfolio
  162. 12.27.5 AB Science SA Recent Developments
  163. 12.28 4SC AG
  164. 12.28.1 4SC AG Company Information
  165. 12.28.2 4SC AG Business Overview
  166. 12.28.3 4SC AG Revenue in Pancreatic and Bile Duct Cancer Drug Business (2021-2026)
  167. 12.28.4 4SC AG Pancreatic and Bile Duct Cancer Drug Product Portfolio
  168. 12.28.5 4SC AG Recent Developments
  169. 12.29 4P-Pharma SAS
  170. 12.29.1 4P-Pharma SAS Company Information
  171. 12.29.2 4P-Pharma SAS Business Overview
  172. 12.29.3 4P-Pharma SAS Revenue in Pancreatic and Bile Duct Cancer Drug Business (2021-2026)
  173. 12.29.4 4P-Pharma SAS Pancreatic and Bile Duct Cancer Drug Product Portfolio
  174. 12.29.5 4P-Pharma SAS Recent Developments
  175. 12.30 3-V Biosciences Inc
  176. 12.30.1 3-V Biosciences Inc Company Information
  177. 12.30.2 3-V Biosciences Inc Business Overview
  178. 12.30.3 3-V Biosciences Inc Revenue in Pancreatic and Bile Duct Cancer Drug Business (2021-2026)
  179. 12.30.4 3-V Biosciences Inc Pancreatic and Bile Duct Cancer Drug Product Portfolio
  180. 12.30.5 3-V Biosciences Inc Recent Developments
13 Report Conclusion
    14 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst